Leucovorin rescue selectively protects normal cells without stimulating tumor growth.
Leucovorin rescue selectively protects normal cells from high-dose methotrexate toxicity by restoring folate-dependent pathways without reducing the antineoplastic efficacy against tumor cells.
The claim is a specific, well-established pharmacological principle regarding the mechanism of leucovorin rescue following high-dose methotrexate therapy. The retrieved literature directly discusses how leucovorin provides systemic protection to normal tissues while allowing high concentration-time exposures against cancer cells. Therefore, the evidence strongly supports the claim.
L. Matherly, C. Barlowe, V. Phillips, I. Goldman. The effects on 4-aminoantifolates on 5-formyltetrahydrofolate metabolism in L1210 cells. A biochemical basis of the selectivity of leucovorin rescue.. 1987. https://doi.org/10.1016/s0021-9258(19)75842-6
Evaluates the biochemical basis and metabolic selectivity of leucovorin rescue in relation to antifolate treatment.
See more details
Stephen B. Howell, B B Chu, W E Wung, B M Metha, John Mendelsohn. Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.. 1981. https://doi.org/10.1172/jci110130
Demonstrates that leucovorin administration provides systemic protection against high-dose methotrexate toxicity without diminishing the therapeutic exposure of malignant cells.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt